Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on a recent publication from the Intergroupe Francophone du Myélome (IFM) on risk assessment in patients with translocation t(4;14) multiple myeloma. According to this study, three subgroups of patients have been identified within the t(4;14) population, each being associated with a distinct outcome depending on the location of the translocation breakpoint in the NSD2 gene. In this interview, Dr Paiva describes the main findings of this study and highlights the value of transitioning from traditional fluorescent in situ hybridization (FISH) to next-generation sequencing (NGS) in myeloma prognostication to characterize abnormalities and predict outcomes with more specificity. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
